Annual report pursuant to Section 13 and 15(d)

EQUITY - Summary of Equity Instruments Other than Options (Details)

v3.24.1
EQUITY - Summary of Equity Instruments Other than Options (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Nov. 15, 2023
Dec. 09, 2022
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
May 31, 2023
Warrants              
Shares              
Issued and Outstanding at beginning of period (in shares)       86,048,837 69,280,403    
Granted (in shares)   200,000   2,970,221 21,112,280    
Vested and Released (in shares)         (4,343,846)    
Cancelled (in shares) (200,000)     (2,087,500)      
Issued and Outstanding at end of period (in shares)       86,931,558 86,048,837 69,280,403  
Exercisable (in shares)       83,971,558      
Weighted - Average Exercise Price Per Share              
Issued and Outstanding at beginning of period (in dollars per share)       $ 1.40 $ 1.19    
Granted (in dollars per share)   $ 0.55   0.63 2.06    
Vested and Released (in dollars per share)         1.26    
Cancelled (in dollars per share) $ 1.75     2.18      
Issued and Outstanding at end of period (in dollars per share)       1.12 $ 1.40 $ 1.19  
Weighted Average Grant Date Fair Value, Exercisable (in dollars per share)       $ 1.11      
Aggregate Intrinsic Value              
Issued and Outstanding at beginning of period       $ 1,081 $ 142,791    
Vested and Released         9,746    
Issued and Outstanding at end of period       0 $ 1,081 $ 142,791  
Aggregate Intrinsic Value, Exercisable       $ 0      
Weighted Average Remaining Contractual Life (in Years)              
Issued and Outstanding       3 years 3 years 10 months 24 days 4 years 8 months 12 days  
Exercisable       3 years      
Warrants | Non-Derivative Warrants              
Shares              
Issued and Outstanding at beginning of period (in shares)       30,673,635 29,156,048    
Granted (in shares)       2,970,221 1,600,000    
Vested and Released (in shares)         (82,413)    
Cancelled (in shares)       (2,087,500)      
Reclassified (in shares)     17,512,280 17,512,280      
Issued and Outstanding at end of period (in shares)       49,068,636 30,673,635 29,156,048  
Exercisable (in shares)       46,108,636      
Weighted Average Remaining Contractual Life (in Years)              
Warrants repriced (in dollars per share)     $ 1.00       $ 2.086
Warrants | Derivative Warrants              
Shares              
Issued and Outstanding at beginning of period (in shares)       55,375,202 40,124,355    
Granted (in shares)       0 19,512,280    
Vested and Released (in shares)         (4,261,433)    
Cancelled (in shares)       0      
Reclassified (in shares)       (17,512,280)      
Issued and Outstanding at end of period (in shares)       37,862,922 55,375,202 40,124,355  
Exercisable (in shares)       37,862,922      
Warrants | Derivative Warrants to Purchase Super Voting Shares              
Weighted Average Remaining Contractual Life (in Years)              
Warrants repriced (in shares)     5,890,922        
Warrants repriced (in dollars per share)     $ 1.00       $ 1.25
Restricted Stock              
Shares              
Issued and Outstanding at beginning of period (in shares)       1,156,319 2,859,151    
Granted (in shares)         86,952    
Vested and Released (in shares)       (1,099,684) (1,789,784)    
Cancelled (in shares)       (54,774)      
Issued and Outstanding at end of period (in shares)       1,861 1,156,319 2,859,151  
Weighted - Average Exercise Price Per Share              
Issued and Outstanding at beginning of period (in dollars per share)       $ 2.45 $ 2.13    
Granted (in dollars per share)         2.05    
Vested and Released (in dollars per share)       2.45 1.96    
Cancelled (in dollars per share)       2.43      
Issued and Outstanding at end of period (in dollars per share)       $ 4.05 $ 2.45 $ 2.13  
Aggregate Intrinsic Value              
Issued and Outstanding at beginning of period       $ 881 $ 9,292    
Vested and Released       526 3,601    
Issued and Outstanding at end of period       $ 1 $ 881 $ 9,292  
Weighted Average Remaining Contractual Life (in Years)              
Issued and Outstanding       8 months 12 days 3 months 18 days 1 year 2 months 12 days